290 related articles for article (PubMed ID: 16461746)
1. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N
Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
6. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
7. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
8. Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells.
Velten FW; Rambow F; Metharom P; Goerdt S
Mol Immunol; 2007 Mar; 44(7):1544-50. PubMed ID: 17023048
[TBL] [Abstract][Full Text] [Related]
9. Sinomenine promotes differentiation but impedes maturation and co-stimulatory molecule expression of human monocyte-derived dendritic cells.
Chen Y; Yang C; Jin N; Xie Z; Fei L; Jia Z; Wu Y
Int Immunopharmacol; 2007 Aug; 7(8):1102-10. PubMed ID: 17570327
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
11. Impaired maturation of monocyte-derived dendritic cells from birch allergic individuals in association with birch-specific immune responses.
Casas R; Skarsvik S; Lindström A; Zetterström O; Duchén K
Scand J Immunol; 2007 Nov; 66(5):591-8. PubMed ID: 17868259
[TBL] [Abstract][Full Text] [Related]
12. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of suplatast tosilate on the differentiation and function of monocyte-derived dendritic cells from patients with asthma.
Tanaka A; Minoguchi K; Samson KT; Oda N; Yokoe T; Tazaki T; Yamamoto Y; Yamamoto M; Ohta S; Adachi M
Clin Exp Allergy; 2007 Jul; 37(7):1083-9. PubMed ID: 17581203
[TBL] [Abstract][Full Text] [Related]
14. Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.
Balabanov S; Appel S; Kanz L; Brossart P; Brümmendorf TH
Ann N Y Acad Sci; 2005 Jun; 1044():168-77. PubMed ID: 15958710
[TBL] [Abstract][Full Text] [Related]
15. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
[TBL] [Abstract][Full Text] [Related]
17. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia].
Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744
[TBL] [Abstract][Full Text] [Related]
18. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
Litzow MR; Dietz AB; Bulur PA; Butler GW; Gastineau DA; Hoering A; Fink SR; Letendre L; Padley DJ; Paternoster SF; Tefferi A; Vuk-Pavlović S
Cytotherapy; 2006; 8(3):290-8. PubMed ID: 16793737
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells.
Yilmaz A; Reiss C; Weng A; Cicha I; Stumpf C; Steinkasserer A; Daniel WG; Garlichs CD
J Leukoc Biol; 2006 Mar; 79(3):529-38. PubMed ID: 16387846
[TBL] [Abstract][Full Text] [Related]
20. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
